Novartis licenses rights to Proteus' IP to develop drugs
Novartis has licensed exclusive global rights to develop and market organ transplant drugs that incorporate Proteus Biomedical's (micro-electromechanical systems for congestive heart failure) sensor-based technologies.
- Medical Devices
- Nanotechnology, Chips, etc.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.